EPEN’s activities are, in part, made possible by the support of our sponsors. Please speak to their representatives during the refreshment breaks at our meetings.
In the meantime, information about our sponsors is listed below along with links to their websites if you’re interested in learning more.
Biocodex develops and markets drugs for patients with severe orphan diseases. In the early 1990’s, our R&D in Compiègne found and developed an anti-epileptic drug indicated for a newly discovered rare and severe epileptic disorder: Dravet Syndrome. Since then, we have been committed to raising awareness on rare epilepsies alongside healthcare professionals, patients and caregivers. Our aim is to provide effective, innovative products and services that help lighten the disease burden for patients and their families.
In 2021, Biocodex was granted the exclusive rights to distribute another product in most European countries on behalf of Orphelia Pharma. This anti-epileptic drug is indicated for the treatment of a severe and rare epileptic disorder in children: West Syndrome.
Working alongside all the relevant stakeholders, Biocodex is committed to improving knowledge for an earlier diagnosis and optimal management of rare epilepsies.
Ethypharm is an independent pharmaceutical company with global reach. It is dedicated to developing innovative drugs, primarily for the treatment of pain, addiction and critical care.
Ethypharm has unique experience of more than 30 years in developing its own portfolio of drugs based on state-of–the-art proprietary technologies.
Ethypharm also develop complex generics that contribute towards optimisation of healthcare costs providing meaningful cost savings to CCG’s and Health Boards without compromising on healthcare delivery for patients.
For further information on Ethypharm UK or any of our medicines please contact us; telephone 01628 551900 or via email.
At Eisai, everything we do is dedicated to giving our first thought to patients and their families through our human health care (hhc) philosophy. We are the European hub of Tokyo-based Eisai Co. Ltd., forming part of a multinational team working across a global network of R&D facilities, manufacturing sites and marketing subsidiaries.
Our collective passion and dedication to patient care is the driving force behind our efforts to discover and develop innovative medicines in a variety of therapeutic areas in which a high unmet medical need remains, including oncology and neurology.
Our mission is clear; we strive to make a significant long-lasting contribution to society in an ethical, compliant and sustainable way by embodying our hhc philosophy in everything we do.
Jazz Pharmaceuticals is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families.
We are dedicated to developing life-changing medicines for people with serious diseases – often with limited or no therapeutic options.
Following the acquisition of GW pharmaceuticals, together we are continuing our commitment to patients and pursuing innovative and differential therapies that establish new or better standards of care in neuroscience and oncology.
LivaNova PLC is a global medical technology and innovation company built on nearly five decades of experience and a relentless commitment to provide hope for patients and their families through innovative medical technologies, delivering life-changing improvements for both the Head and Heart.
Headquartered in London, LivaNova employs approximately 3,000 employees and has a presence in more than 100 countries for the benefit of patients, healthcare professionals and healthcare systems worldwide.
Neuraxpharm is a leading European specialty pharmaceutical company focused on the treatment of central nervous system disorders (CNS) with a direct presence in 19 countries.
Neuraxpharm brought its extensive 35 years’ experience to the UK in 2019, establishing a UK affiliate, which aims to deliver meaningful improvements in the lives of British patients living with neurological and psychiatric disorders.
Neuro Event Labs Nelli uses an easy workflow and platform combining both AI and human expertise, without EEG, which is revolutionary.
It uses a Personal Recording Rnit, which includes a computer, camera, and microphone, which is placed over the bed, at the patient’s home or at the hospital. No wearables are involved.
An examination can last for 24 hours to 28 days or more with the captured data run through a series of individual algorithms in the AWS cloud. A team of experts review the results produced, classify, and produce a report via the easy to use dashboard to the referring clinician.
Nelli can be used for pre-screening, as a diagnostic tool or to assess treatment.
Most epilepsy patients respond well to medication that reduces the frequency of epileptic seizures. However, 0-30% of patients with epilepsy don’t see any improvements with anti-epileptic drugs and many find the side effects of treatment difficult to cope with.
For patients with refractory epilepsy, a ketogenic diet can provide a way forward. At Nutrica Ketogenics, we have been supporting patients with drug resistant epilepsy for over 25 years via our comprehensive line of ketogenic medical foods aimed at helping make the ketogenic diet easier for adults and children living with epilepsy, and their families.
Fewer seizures make for a better quality of life, and we are researching new ketogenic products to help make an even bigger difference to the people who need it.
Proveca Ltd is a UK based pharmaceutical company specialising in the development and licensing of off-patent medicines for children throughout Europe.
Marketing approval (product licence) is gained via a Paediatric Use Marketing Authorisation (PUMA), a regulatory route developed specifically for licensing off-patent medicines for children in Europe.
Proveca’s first PUMA (Sialanar) was granted in September 2016.
SERB Pharmaceuticals represents the combination of SERB, BTG Specialty Pharmaceuticals and Veriton Pharma Ltd to form a new, growing specialty pharmaceutical company focused on critical care and rare diseases.
We make treating complex and life-threatening conditions possible; supporting clinicians, healthcare systems and governments while offering hope to patients and their families.
Improving patients’ quality of life and offering hope is what motivates and inspires us.